NeoGenomics, Inc.

Informe acción NasdaqCM:NEO

Capitalización de mercado: US$2.0b

Salud financiera de hoja de balance de NeoGenomics

Salud financiera controles de criterios 4/6

NeoGenomics tiene un patrimonio de los accionistas total de $908.2M y una deuda total de $540.4M, lo que sitúa su ratio deuda-patrimonio en 59.5%. Sus activos y pasivos totales son $1.6B y $732.9M respectivamente.

Información clave

59.5%

Ratio deuda-patrimonio

US$540.38m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$387.81m
PatrimonioUS$908.21m
Total pasivoUS$732.90m
Activos totalesUS$1.64b

Actualizaciones recientes sobre salud financiera

Recent updates

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Mar 30
Investors Interested In NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues

Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Dec 26
Investor Optimism Abounds NeoGenomics, Inc. (NASDAQ:NEO) But Growth Is Lacking

Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Aug 23
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?

Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

Jul 16
Risks To Shareholder Returns Are Elevated At These Prices For NeoGenomics, Inc. (NASDAQ:NEO)

NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

Apr 18
NeoGenomics (NASDAQ:NEO) Is Making Moderate Use Of Debt

We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

Jan 10
We Think NeoGenomics (NASDAQ:NEO) Has A Fair Chunk Of Debt

NeoGenomics: Market Punishment Continues, But Looks Justified

Sep 30

NeoGenomics grants CEO restricted shares, stock options

Aug 17

Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

Aug 10
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt

NeoGenomics rises ~14% on strong Q2 result

Aug 09

NeoGenomics gets new CEO

Jul 21

NeoGenomics: Refrain From Portfolio Allocation, Negligible Upside Potential

Jun 28

Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Apr 22
Is NeoGenomics (NASDAQ:NEO) Using Too Much Debt?

Neogenomics: Poor Performance, CEO Departure Create Downward Share Price Spiral

Apr 08

Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Feb 11
Why NeoGenomics, Inc. (NASDAQ:NEO) Could Be Worth Watching

Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

Jan 07
Is NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?

NeoGenomics: Gambling On Growth

Dec 16

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($590.2M) de NEO superan a sus pasivos a corto plazo ($296.4M).

Pasivo a largo plazo: Los activos a corto plazo de NEO ($590.2M) superan a sus pasivos a largo plazo ($436.5M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (16.8%) de NEO se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de NEO ha crecido de 20.4% a 59.5% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NEO tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si NEO tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera